Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2′- deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7499-7507

  Seo, Yuji ^a   Yan, Tao ^a   Schupp, Jane E ^a   Radivoyevitch, Tomas ^a   Kinsella, Timothy J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; ALDEHYDE OXIDASE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLIOBLASTOMA; HUMANS; IDOXURIDINE; MICE; MICE, NUDE; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27144494965     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1138     Document Type: Article

References (27)

1. Lewandowski GA, Cheng YC. Mechanism and mode of action of 5-iodo-2-pyrimidinone 2′-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells. Mol Pharmacol 1991;39:27-33.
2. Efange SM, Alessi EM, Shih HC, et al. Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2′- deoxyribonucleosides. J Med Chem 1985;28:904-10.
3. Chang CN, Doong SL, Cheng YC. Conversion of 5-iodo-2-pyrimidinone- 2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design. Biochem Pharmacol 1992;43:2269-73.
4. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56:53-102.
5. Kinsella TJ. An approach to the radiosensitization of human tumors. Cancer J Sci Am 1996;2:184-93.
6. Lawrence TS, Davis MA, McKeever PE, et al. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo. Cancer Res 1991;51:3900-5.
7. Kinsella TJ, Glennon MC, Kunugi KA, et al. In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5′-amino-5′-deoxythymidine in normal mouse tissues and two human colon cancer xenografts. Clin Cancer Res 1996;2:981-9.
8. Kinsella TJ, Kunugi KA, Vielhuber KA, et al. Preclinical evaluation of 5-iodo-2′-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin Cancer Res 1998;4:99-109.
9. Kinsella TJ, Collins J, Rowland J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988;6:871-9.
10. Chang AE, Collins JM, Speth PA, et al. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases. J Clin Oncol 1989;7:662-8.
11. Urtasun RC, Cosmatos D, Del Rowe J, et al. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 1993;27:207-14.
12. Epstein AH, Lebovics RS, Goffman T, et al. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J Natl Cancer Inst 1994;86:1775-80.
13. Sondak VK, Robertson JM, Sussman JJ, et al. Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann Surg Oncol 1998;5:106-12.
14. Eisbruch A, Robertson JM, Johnston CM, et al. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study. J Clin Oncol 1999;17:31-40.
15. Schulz CA, Mehta MP, Badie B, et al. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. Int J Radiat Oncol Biol Phys 2004;59:1107-15.
16. Kinsella TJ, Schupp JE, Davis TW, et al. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2′- deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design. Clin Cancer Res 2000;6:3670-9.
17. Kinsella TJ, Kunugi KA, Vielhuber KA, et al. An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res 1994;54:2695-700.
18. Kinsella TJ, Vielhuber KA, Kunugi KA, et al. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′- deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Res 2000;6:1468-75.
19. Seo Y, Yan T, Schupp JE, et al. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose. Clin Cancer Res 2004;10:7520-8.
20. Belanger K, Collins JM, Klecker RW, Jr. Technique for detection of DNA nucleobases by reversed-phase high-performance liquid chromatography optimized for quantitative determination of thymidine substitution by iododeoxyuridine. J Chromatogr 1987;417:57-63.
21. Kwon Y. Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists. New York: Kluwer Academic/Plenum Publishers: 2001. p. 3-27.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
23. Terao M, Kurosaki M, Marini M, et al. Purification of the aldehyde oxidase homolog 1 (AOH1) protein and cloning of the AOH1 and aldehyde oxidase homolog 2 (AOH2) genes. Identification of a novel molybdoflavoprotein gene cluster on mouse chromosome 1. J Biol Chem 2001;276:46347-63.
24. Fabre G, Seither R, Goldman ID. Hydroxylation of 4-amino-antifolates by partially purified aldehyde oxidase from rabbit liver. Biochem Pharmacol 1986;35:1325-30.
25. Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 2004;32:89-97.
26. Kuhl PW. Excess-substrate inhibition in enzymology and high-dose inhibition in pharmacology: a reinterpretation [corrected]. Biochem J 1994;298:171-80.
27. Klecker RW, Cysyk RL, Collins JM. Metabolism of zebularine and its analogs by aldehyde oxidase in human, murine, and rat liver. Proc Am Assoc Cancer Res 2005;46:604.